We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Statistically significant results demonstrate cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily in the XanaHES dose escalation study Statistically significant...
Significant milestone achieved for XanADu, with final patient enrolled into trial A total of 186 patients have been enrolled into XanADu, surpassing initial target of 174 Final...
/newsletter/barneyc/759/actinogen-medical-received-fda-approval-for-alzheimer-treatment
Australian CSIRO and university funded AIBL study links excess cortisol and Alzheimer’s disease. Anti-Alzheimer’s compound Xanamem™ in clinical testing blocks high cortisol (“stress”...
NEW YORK, Dec. 8 /PRNewswire/ -- The American Stock Exchange(R) (Amex) will launch trading in options on Friday, December 9, 2005 on the following New York Stock Exchange and Nasdaq Stock Market...
NEW YORK, Dec. 8 /PRNewswire/ -- The American Stock Exchange(R) (Amex) will launch trading in options on Friday, December 9, 2005 on the following New York Stock Exchange and Nasdaq Stock Market...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.002 | 8.33333333333 | 0.024 | 0.028 | 0.024 | 4607919 | 0.02523988 | DE |
4 | -0.005 | -16.1290322581 | 0.031 | 0.0335 | 0.024 | 4734462 | 0.02798046 | DE |
12 | 0 | 0 | 0.026 | 0.0335 | 0.023 | 4580940 | 0.02689198 | DE |
26 | -0.036 | -58.064516129 | 0.062 | 0.099 | 0.021 | 10796670 | 0.04144031 | DE |
52 | 0.004 | 18.1818181818 | 0.022 | 0.099 | 0.02 | 7290185 | 0.0407656 | DE |
156 | -0.139 | -84.2424242424 | 0.165 | 0.18 | 0.015 | 3411843 | 0.04955072 | DE |
260 | -0.01 | -27.7777777778 | 0.036 | 0.1975 | 0.015 | 4368306 | 0.05721491 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions